1-3 of 3
Hideko Nakahara
Close
Sort by
Journal Articles

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Norihiro Nishimoto, Kimio Terao, Toru Mima, Hideko Nakahara, Nobuhiro Takagi, Takahiro Kakehi
Journal: Blood
Blood (2008) 112 (10): 3959–3964.
https://doi.org/10.1182/blood-2008-05-155846
Published: 2008
Journal Articles

Anti-Interleukin 6 Receptor Monoclonal Antibody Therapy Reduced Serum Interleukin 4 and IgE Production in Castleman’s Disease.

Hideko Nakahara, MD, Naoko Hoshino-Yoshio, MD, Yuzuru Kanakura, MD, Yasuo Ikeda, MD, Minoru Nakamura, MD, Shuji Nakano, MD, Toshio Tanaka, MD, Takeshi Sasaki, MD, Kiyoshi Nishioka, MD, Masamichi Hara, MD, Hirokuni Taguchi, MD, Yukihiko Kimura, MD, Yoshiro Kato, MD, Hideki Asaoku, MD, Fumio Kodama, MD, Katsuyuki Aozasa, MD, Takeshi Johkoh, MD, Tadamitsu Kishimoto, MD, Norihiro Nishimoto, MD, for the Japanese, MRA Study Group on MCD
Journal: Blood
Blood (2005) 106 (11): 1510.
https://doi.org/10.1182/blood.V106.11.1510.1510
Published: 2005
Journal Articles

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Clinical Trials & Observations
Norihiro Nishimoto, Yuzuru Kanakura, Katsuyuki Aozasa, Takeshi Johkoh, Minoru Nakamura, Shuji Nakano, Nobuaki Nakano, Yasuo Ikeda, Takeshi Sasaki, Kiyoshi Nishioka, Masamichi Hara, Hirokuni Taguchi, Yukihiko Kimura, Yoshiro Kato, Hideki Asaoku, Shunichi Kumagai, Fumio Kodama, Hideko Nakahara, Keisuke Hagihara, Kazuyuki Yoshizaki, Tadamitsu Kishimoto
Journal: Blood
Blood (2005) 106 (8): 2627–2632.
https://doi.org/10.1182/blood-2004-12-4602
Published: 2005